Cabozantinib and nivolumab for renal cell carcinoma.
Luke
L
Worley
D000813:Anilides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D000077594:Nivolumab; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D000813:Anilides; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011725:Pyridines; C558660:cabozantinib; D000077594:Nivolumab